Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 482

1.

Bullöses Pemphigoid mit linearen Läsionen und Antikörpern ausschließlich gegen die lösliche Ektodomäne von BP180 (LAD-1).

Mahmoudi H, Toosi R, Kamyab K, Zillikens D, Schmidt E, Daneshpazhooh M.

J Dtsch Dermatol Ges. 2019 Sep;17(9):933-936. doi: 10.1111/ddg.13898_g. German. No abstract available.

PMID:
31538747
2.

Gene-diet interactions associated with complex trait variation in an advanced intercross outbred mouse line.

Vorobyev A, Gupta Y, Sezin T, Koga H, Bartsch YC, Belheouane M, Künzel S, Sina C, Schilf P, Körber-Ahrens H, Beltsiou F, Lara Ernst A, Khil'chenko S, Al-Aasam H, Manz RA, Diehl S, Steinhaus M, Jascholt J, Kouki P, Boehncke WH, Mayadas TN, Zillikens D, Sadik CD, Nishi H, Ehlers M, Möller S, Bieber K, Baines JF, Ibrahim SM, Ludwig RJ.

Nat Commun. 2019 Sep 10;10(1):4097. doi: 10.1038/s41467-019-11952-w.

3.

Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.

Sadik CD, Langan EA, Grätz V, Zillikens D, Terheyden P.

Front Immunol. 2019 Aug 14;10:1934. doi: 10.3389/fimmu.2019.01934. eCollection 2019.

4.

BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.

Ali OH, Bomze D, Ring S, Berner F, Fässler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik CD, Flatz L.

J Am Acad Dermatol. 2019 Aug 23. pii: S0190-9622(19)32650-7. doi: 10.1016/j.jaad.2019.08.045. [Epub ahead of print]

5.

Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease.

Sezin T, Murthy S, Attah C, Seutter M, Holtsche MM, Hammers CM, Schmidt E, Meshrkey F, Mousavi S, Zillikens D, Nunn MA, Sadik CD.

JCI Insight. 2019 Aug 8;4(15). pii: 128239. doi: 10.1172/jci.insight.128239. eCollection 2019 Aug 8.

6.

Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LAD-1).

Mahmoudi H, Toosi R, Kamyab K, Zillikens D, Schmidt E, Daneshpazhooh M.

J Dtsch Dermatol Ges. 2019 Sep;17(9):933-935. doi: 10.1111/ddg.13898. Epub 2019 Jul 28. No abstract available.

PMID:
31353797
7.

Optimization of reference gene panels for gene expression analysis in preclinical models of inflammatory skin diseases.

Braun A, Sezin T, Bezdek S, Doxastaki I, Zillikens D, Busch HS, Sadik CD.

Exp Dermatol. 2019 Aug;28(8):985-988. doi: 10.1111/exd.13989. Epub 2019 Jul 3.

PMID:
31177560
8.

The Sphingosine-1-Phosphate Receptor Modulator Fingolimod Aggravates Murine Epidermolysis Bullosa Acquisita.

Thieme M, Bieber K, Sezin T, Wannick M, Gupta Y, Kalies K, Ludwig RJ, Mousavi S, Zillikens D, Sadik CD.

J Invest Dermatol. 2019 Nov;139(11):2381-2384.e3. doi: 10.1016/j.jid.2019.03.1159. Epub 2019 Jun 7. No abstract available.

PMID:
31176709
9.

First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.

Sadik CD, Thieme M, Zillikens D, Terheyden P.

J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e406-e407. doi: 10.1111/jdv.15714. Epub 2019 Jun 13. No abstract available.

PMID:
31131924
10.

Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low-molecular-weight heparin tinzaparin sodium.

Gutjahr A, Heck F, Emtenani S, Hammers AK, Hundt JE, Muck P, Siegel DL, Schmidt E, Stanley JR, Zillikens D, Hammers CM.

Br J Dermatol. 2019 Sep;181(3):593-594. doi: 10.1111/bjd.18156. Epub 2019 Jun 5. No abstract available.

PMID:
31124130
11.

Ein ungewöhnlicher Fall von Lichen ruber planus mit vorausgegangenem bullösem Pemphigoid bei einem 20-jährigen Patienten.

Witte M, Zillikens D, Sadik CD.

J Dtsch Dermatol Ges. 2019 May;17 Suppl 2:7-8. doi: 10.1111/ddg.13780. No abstract available.

PMID:
31037852
12.

Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis.

Langan EA, Künstner A, Miodovnik M, Zillikens D, Thaçi D, Baines JF, Ibrahim SM, Solbach W, Knobloch JK.

Br J Dermatol. 2019 Apr 15. doi: 10.1111/bjd.17989. [Epub ahead of print]

PMID:
30985920
13.

Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.

Langan EA, Kümpers C, Graetz V, Perner S, Zillikens D, Terheyden P.

Dermatol Ther. 2019 May;32(3):e12901. doi: 10.1111/dth.12901. Epub 2019 Apr 29.

PMID:
30974014
14.

[Anti-laminin 332 mucous membrane pemphigoid with irreversible ocular and tracheobronchial involvement : Delayed diagnosis of a severe autoimmune bullous disease].

Syring FM, Zillikens D, Schmidt E, Kasperkiewicz M.

Hautarzt. 2019 May;70(5):367-370. doi: 10.1007/s00105-019-4402-z. German.

PMID:
30963224
15.

Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin.

Lau I, Goletz S, Holtsche MM, Zillikens D, Fechner K, Schmidt E.

J Am Acad Dermatol. 2019 Nov;81(5):1195-1197. doi: 10.1016/j.jaad.2019.03.077. Epub 2019 Apr 3. No abstract available.

PMID:
30953703
16.

GPR15 is not critically involved in the regulation of murine psoriasiform dermatitis.

Sezin T, Kempen L, Meyne LM, Mousavi S, Zillikens D, Sadik CD.

J Dermatol Sci. 2019 Apr;94(1):196-204. doi: 10.1016/j.jdermsci.2019.01.008. Epub 2019 Mar 12.

PMID:
30935778
17.

[Therapy of pemphigus].

van Beek N, Zillikens D, Schmidt E.

Hautarzt. 2019 Apr;70(4):243-253. doi: 10.1007/s00105-019-4385-9. Review. German.

PMID:
30887081
18.

Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.

Grätz V, Langan EA, Neumann A, Zillikens D, Terheyden P.

Melanoma Res. 2019 Oct;29(5):516-521. doi: 10.1097/CMR.0000000000000597.

PMID:
30870272
19.

[Anti-p200 pemphigoid].

Holtsche MM, Goletz S, Zillikens D.

Hautarzt. 2019 Apr;70(4):271-276. doi: 10.1007/s00105-019-4376-x. Review. German.

PMID:
30868255
20.

Identification of the recently described plasminogen gene mutation p.Lys330Glu in a family from Northern Germany with hereditary angioedema.

Recke A, Massalme EG, Jappe U, Steinmüller-Magin L, Schmidt J, Hellenbroich Y, Hüning I, Gillessen-Kaesbach G, Zillikens D, Hartmann K.

Clin Transl Allergy. 2019 Feb 14;9:9. doi: 10.1186/s13601-019-0247-x. eCollection 2019.

21.

Black tea dressings - a rapidly effective treatment for facial dermatitis.

Witte M, Krause L, Zillikens D, Shimanovich I.

J Dermatolog Treat. 2019 Dec;30(8):785-789. doi: 10.1080/09546634.2019.1573306. Epub 2019 Feb 3.

PMID:
30668184
22.

Detection of u-serrated patterns in direct immunofluorescence images of autoimmune bullous diseases by inhibition-augmented COSFIRE filters.

Shi C, Meijer JM, Guo J, Azzopardi G, Diercksr GFH, Schmidt E, Zillikens D, Jonkman MF, Petkov N.

Int J Med Inform. 2019 Feb;122:27-36. doi: 10.1016/j.ijmedinf.2018.11.007. Epub 2018 Nov 28.

PMID:
30623781
23.

Topically applied low-dose calcitriol ameliorates atopic eyelid dermatitis.

Tukaj S, Zillikens D, Kasperkiewicz M.

JAAD Case Rep. 2018 Nov 27;5(1):5-6. doi: 10.1016/j.jdcr.2018.09.012. eCollection 2019 Jan. No abstract available.

24.

[Immunoadsorption in dermatology].

Hübner F, Kasperkiewicz M, Zillikens D, Schmidt E.

Hautarzt. 2019 Jan;70(1):51-63. doi: 10.1007/s00105-018-4315-2. Review. German.

PMID:
30519749
25.

Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases.

Wannick M, Bezdek S, Guillen N, Thieme M, Meshrkey F, Mousavi S, Seeling M, Nimmerjahn F, Mócsai A, Zillikens D, Sezin T, Sadik CD.

Pharmacol Res Perspect. 2018 Nov 8;6(6):e00438. doi: 10.1002/prp2.438. eCollection 2018 Dec.

26.

Diagnosis of Autoimmune Blistering Diseases.

Witte M, Zillikens D, Schmidt E.

Front Med (Lausanne). 2018 Nov 2;5:296. doi: 10.3389/fmed.2018.00296. eCollection 2018. Review.

27.

[59/f with oral and nasal mucosal erosions : Preparation for the specialist examination: part 18].

Witte M, Zillikens D.

Hautarzt. 2018 Nov;69(Suppl 2):157-161. doi: 10.1007/s00105-018-4284-5. German. No abstract available.

PMID:
30374548
28.

Post-orf epidermolysis bullosa acquisita.

Daneshpazhooh M, Mahmoudi H, Toosi R, Tavakolpour S, Schmidt E, Zillikens D.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e118-e119. doi: 10.1111/jdv.15299. Epub 2018 Nov 15. No abstract available.

PMID:
30357964
29.

Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis.

Bezdek S, Leng L, Busch H, Mousavi S, Rades D, Dahlke M, Zillikens D, Bucala R, Sadik CD.

Front Immunol. 2018 Oct 2;9:2262. doi: 10.3389/fimmu.2018.02262. eCollection 2018.

30.

Unmet Needs in Pemphigoid Diseases: An International Survey Amongst Patients, Clinicians and Researchers.

Lamberts A, Yale M, Grando SA, Horváth B, Zillikens D, Jonkman MF.

Acta Derm Venereol. 2019 Feb 1;99(2):224-225. doi: 10.2340/00015555-3052. No abstract available.

31.

Grover disease and bullous pemphigoid: a clinicopathological study of six cases.

Ellenbogen E, Geller S, Azrielant S, Zeeli T, Goldberg I, Schmidt E, Zillikens D, Mrowietz U, Sherman S, Mercer S, Didkovsky E, Hodak E, Sprecher E.

Clin Exp Dermatol. 2019 Jul;44(5):524-527. doi: 10.1111/ced.13789. Epub 2018 Sep 27.

PMID:
30264538
32.

Immunoadsorption of Desmoglein-3-Specific IgG Abolishes the Blister-Inducing Capacity of Pemphigus Vulgaris IgG in Neonatal Mice.

Hofrichter M, Dworschak J, Emtenani S, Langenhan J, Weiß F, Komorowski L, Zillikens D, Stöcker W, Probst C, Schmidt E, Goletz S.

Front Immunol. 2018 Sep 3;9:1935. doi: 10.3389/fimmu.2018.01935. eCollection 2018.

33.

IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid.

Chakievska L, Holtsche MM, Künstner A, Goletz S, Petersen BS, Thaci D, Ibrahim SM, Ludwig RJ, Franke A, Sadik CD, Zillikens D, Hölscher C, Busch H, Schmidt E.

J Autoimmun. 2019 Jan;96:104-112. doi: 10.1016/j.jaut.2018.09.003. Epub 2018 Sep 13.

34.

A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid.

Goletz S, Probst C, Komorowski L, Schlumberger W, Fechner K, van Beek N, Holtsche MM, Recke A, Yancey KB, Hashimoto T, Antonicelli F, Di Zenzo G, Zillikens D, Stöcker W, Schmidt E.

Br J Dermatol. 2019 Jan;180(1):149-156. doi: 10.1111/bjd.17202. Epub 2018 Nov 1.

PMID:
30216412
35.

Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.

Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, Ishii N, Hashimoto T, Ludwig RJ.

Orphanet J Rare Dis. 2018 Sep 4;13(1):153. doi: 10.1186/s13023-018-0896-1.

36.

Diagnostik blasenbildender Autoimmundermatosen.

van Beek N, Zillikens D, Schmidt E.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1077-1092. doi: 10.1111/ddg.13637_g. Review.

PMID:
30179341
37.

Diagnosis of autoimmune bullous diseases.

van Beek N, Zillikens D, Schmidt E.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1077-1091. doi: 10.1111/ddg.13637. Review.

PMID:
30179336
38.

Adjuvante Behandlung des schweren/refraktären bullösen Pemphigoids mit Protein-A-Immunadsorption.

Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Süfke S, Muck P, Zillikens D, Schmidt E.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1109-1119. doi: 10.1111/ddg.13642_g.

PMID:
30179332
39.

Adjuvant treatment of severe/refractory bullous pemphigoid with protein A immunoadsorption.

Hübner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, Hübner J, Süfke S, Muck P, Zillikens D, Schmidt E.

J Dtsch Dermatol Ges. 2018 Sep;16(9):1109-1118. doi: 10.1111/ddg.13642.

PMID:
30179319
40.

The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.

Wannick M, Assmann JC, Vielhauer JF, Offermanns S, Zillikens D, Sadik CD, Schwaninger M.

Front Immunol. 2018 Aug 14;9:1890. doi: 10.3389/fimmu.2018.01890. eCollection 2018.

41.

The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts.

Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, Benoit S, El-Chennawy F, Eldarouti M, Eming R, Gläser R, Günther C, Hadaschik E, Homey B, Lieb W, Peitsch WK, Pföhler C, Robati RM, Saeedi M, Sárdy M, Sticherling M, Uzun S, Worm M, Zillikens D, Ibrahim S, Vidarsson G, Schmidt E; German AIBD Genetic Study Group.

Front Immunol. 2018 Aug 2;9:1788. doi: 10.3389/fimmu.2018.01788. eCollection 2018.

42.

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Koga H, Kasprick A, López R, Aulí M, Pont M, Godessart N, Zillikens D, Bieber K, Ludwig RJ, Balagué C.

Front Immunol. 2018 Jul 12;9:1558. doi: 10.3389/fimmu.2018.01558. eCollection 2018.

43.

Immunohistochemical diagnosis of mucous membrane pemphigoid.

Shimanovich I, Nitz JM, Witte M, Zillikens D, Rose C.

J Oral Pathol Med. 2018 Jul;47(6):613-619. doi: 10.1111/jop.12732. Epub 2018 May 30.

PMID:
29752861
44.

Correction: Paraneoplastic autoimmune multiorgan syndrome and paraneoplastic pemphigus describe the same spectrum of disease pathology.

Payne AS, Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Amagai M.

Nat Rev Dis Primers. 2018 May 11;4:18032. doi: 10.1038/nrdp.2018.32.

PMID:
29749393
45.

HLA alleles in British Caucasians with mucous membrane pemphigoid.

Hübner F, Setterfield J, Recke A, Zillikens D, Schmidt E, Dart J, Ibrahim S; MMP Study Group 2009.

Eye (Lond). 2018 Sep;32(9):1540-1541. doi: 10.1038/s41433-018-0092-5. Epub 2018 May 10. No abstract available.

46.

Non-Uremic Calciphylaxis.

Holtsche MM, Zillikens D, Shimanovich I.

Dtsch Arztebl Int. 2018 Apr 13;115(15):265. doi: 10.3238/arztebl.2018.0265. No abstract available.

47.

Does the gastrointestinal microbiome contribute to the 'obesity paradox' in melanoma survival?

Langan EA, Grätz V, Billmann F, Zillikens D, Terheyden P.

Br J Dermatol. 2018 Jul;179(1):225-226. doi: 10.1111/bjd.16681. Epub 2018 May 13. No abstract available.

PMID:
29663324
48.

Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Mihai S, Hirose M, Wang Y, Thurman JM, Holers VM, Morgan BP, Köhl J, Zillikens D, Ludwig RJ, Nimmerjahn F.

Front Immunol. 2018 Mar 16;9:535. doi: 10.3389/fimmu.2018.00535. eCollection 2018.

49.

Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score.

Holtsche MM, Goletz S, van Beek N, Zillikens D, Benoit S, Harman K, Walton S, English J, Sticherling M, Chapman A, Levell NJ, Groves R, Williams HC, König IR, Schmidt E; members of the BLISTER Study Group.

Br J Dermatol. 2018 Oct;179(4):918-924. doi: 10.1111/bjd.16553. Epub 2018 Jul 5.

PMID:
29607480
50.

Paederus dermatitis - touched by champion flies - three clinical manifestations of pederin toxin-inflicted dermatitis.

Schunkert EM, Aschoff NS, Grimmer F, Wiemann C, Zillikens D.

Int J Dermatol. 2018 Aug;57(8):989-991. doi: 10.1111/ijd.13968. Epub 2018 Mar 30. No abstract available.

PMID:
29603192

Supplemental Content

Loading ...
Support Center